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1. Introduction
Estrogen plays a principal role in skeletal growth and bone homeostasis. In women, estrogen
deficiency after menopause accelerates frequently osteoclastic bone resorption. It was believed
that the accelerated phase in women is most apparent during the first 3 to 5 years after
menopause, involved unproportional loss of trabecular bone [1].
We know that the mechanisms of how estrogen deficiency causes bone losses are complex.
Researches during the last decade have demonstrated that estrogen regulates bone homeo‐
stasis through unexpected regulatory effects on the immune system and on oxidative stres and
direct effects on bone cells [2].
We review how the differential effects of estrogen on cortical and trabecular bone might occur
and how estrogen might interact with other age-related processes. Estrogen has three funda‐
mental effects on bone metabolism:
1. It inhibits the activation of bone remodeling and the initiation of new basic multicellular
units (BMUs);
2. It inhibits differentiation and promotes apoptosis of osteoclasts, therefore bone resorption
reduces and
3. While estrogen suppresses self-regeneration of early mesenchymal progenitors, it
organizes the commitment and differentiation and prevents apoptosis of osteoblastic cells,
therefore bone formation is maintaining at the cellular level [1].
In this review, we summarized each of these actions of estrogen Figure 1,2.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. The effects of estrogen on the bone cells
At the tissue level, estrogen reduces bone turnover [4]. It would appear that osteocytes may
regulate the activation of bone remodeling via connections with bone lining cells [5]. It is
likely that  the antiremodeling effects  of  estrogen are mediated via  the osteocyte.  Osteo‐
cytes are cells embedded within the bone matrix, derived from the osteoblast that helps to
bone remodeling. The bone lining cells comprise a subpopulation of the osteoblast family.
These cells  are related with the bone surface at sites where a thin no mineralized colla‐
gen layer is present. The bone lining cells migrate to form a canopy over the remodeling
area,  especially  at  sites  adjacent  to  osteoclasts  [6,7].  Indeed,  withdrawal  of  estrogen  is
associated  with  increased  apoptosis  of  osteocytes  in  humans  [8].  Recent  studies  have
reported that serum estradiol levels are inversely associated with serum levels of the key
inhibitor of  Wnt signaling produced by osteocytes,  sclerostin,  and estrogen treatment of
postmenopausal women reduces circulating sclerostin levels [9,10]. Moreover, it has been
suggested that Wnt/β-catenin signaling is important to respond to mechanical strain of the
osteocyte, and this response also depends on estrogen receptor α (ERα). Wnt signaling is
interrupted  in  the  mesenchyme,  osteoblast  differantiation  is  reduced  and  the  skeletal
development is affected [11]. Thus there is a likely important argument between estrogen
and Wnt signaling pathways mediated by the osteocyte [1] Figure 1.
Figure 1. Schematic of the bone remodeling compartment [3] The bone remodeling compartment (BRC) consists of the
cells comprising the basic multicellular unit (BMU)-osteoclasts (OCs), osteoblasts (OBs), and osteocytes-as well as the
cover bone-lining cells and capillary. These cells are connected with gap junctions. Note also the potential direct physi‐
cal contact between OCs and OBs, which would allow for signaling between these cells [3].
Estrogen suppresses both directly and indirectly bone resorption [1]. The dominant acute effect
of estrogen is blocking the new osteoclast formation. In addition, estrogen also modulates
RANK (Receptor activator of nuclear factor κB) signaling in osteoclastic cells [12,13] and
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induces apoptosis of osteoclasts [14,15]. Osteoclasts are cells of hematopoietic origin respon‐
sible for resorbing bone. These are originated from proliferation that occurs by cytokines and
differantiation of the monocyte precursors. They are located on endosteal surfaces within the
Haversian system and on the periosteal surface [7].
Osteoclast differantiation is supported by cells of the osteoblast lineage. Osteoblast lineage
cells consist of osteoblasts, osteocytes and bone lining cells [7]. Osteoclast differantiation
process is facilitated by stromal cells of bone marrow that provides physical support to
immature OCs. The basic cytokines, need to OC formation under basal conditions are RANKL
(Receptor activator of nuclear factor kappa-B ligand) and M-CSF (Macrophage colony-
stimulating factor). These factors are produced by major stromal cells of bone marrow, OBs
and active T cells. RANKL is a TNF superfamily member. RANKL links transmembrane
receptor RANK expressed from OC surface and OC precursors. RANKL also links OPG
(Osteoprotegerin), a soluble fake receptor produced by several hemapoietic cells. Therefore
OPG functions as an power antiosteoclastogenic cytokine, secreting RANKL and blocking its
binding to RANK. RANKL promotes differantiation of OC precursors from early stage of
maturation to full maturation (multinucleated OCs) [16] Figure 2.
Figure 2. Working model for estrogen regulation of bone turnover via effects on osteocytes, osteoblasts, osteoclasts,
and T-cells [3] The main effect of estrogen is inhibition of bone remodeling, likely via the osteocyte. Estrogen also in‐
hibits bone resorption, by direct effects on osteoclasts, although effects of estrogen on osteoblast/osteocyte and T cell
regulation of osteoclasts likely also play a role. Estrogen deficiency associated with a gap between bone resorption and
formation, likely due to the loss of the effects of estrogen on decreasing osteoblast apoptosis, oxidative stres, osteoblas‐
tic NF-κB activity, and perhaps other, as yet undefined mechanisms [3].
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Detection of molecular mekanisms that are regulate the osteoclast formation and activation
won a big acceleration by survey of RANK/RANKL signal system. M-CSF expression that is
secreted by osteoblastic stromal cells need to differentiation to osteoclasts of progenitor cells
but, M-CSF expression is not itself sufficient to differentiation of osteoclast. RANKL ekspres‐
sion by osteoblastic stromal cells and RANK expression by osteoclast precursors need to be
completed osteoclast differentiation [17] Figure 3.
Osteoblasts are cell of mesenchymal origin responsible for forming bone. These cells are found
along the bone surface at sites of active bone formation. The principal function of the osteo‐
blasts is bone formation [17].
Finally, estrogen is important for the maintenance of bone formation. Human studies show that
acute (3 weeks) estrogen deficiency [18] is associated with a fall in bone-formation markers.
Chronically estrogen deficient increased both bone-resorption and bone-formation markers
[19]. It also appears that the effects of estrogen on progenitor and osteoblastic cells may be stage-
specific. Thus, estrogen reduces the self-innovation of early mesenchymal progenitors [20].
Figure 3. Cells and cytokines responsible for physiological OC renewal. OC precursors may differentiate from the pop‐
ulation of monocytes/macrophages. When RANKL binds to receptor RANK in the presence of the trophic factor M-
CSF, which in turn binds to its receptor, colony-stimulating factor receptor 1 (c-Fms), OC precursors differentiate and
fuse together to multinucleated bone-resorbing OCs. Under physiological conditions the dominant source of RANKL
and M-CSF in the bone marrow microenvironment is from the bone-forming cells, the OBs, and their stromal cell (SC)
precursors.
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It  was  reported  that  osteoblasts,  osteocytes  and  osteoclasts  express  functional  estrogen
receptors (ERs). These receptors are also expressed in bone marrow stromal cells (SCs), the
precursors of osteoblasts [21-24]. Estrogen signals through two receptors, ERalpha and beta
[21]. Bone cells contain both receptors, but their distributions within bone are not homoge‐
neous. In hümans, ER alpha is the predominant in cortical bone, but ER beta is predomi‐
nant in trabecular bone. Although many estrogenic effects are mediated by nuclear ERs,
some effects originate in the plazma membrane. Estrogen produces rapid effects in various
cell  types such as bone cells.  These nongenomic effects are due to signaling by a mem‐
brane receptor. The induce OC apoptosis and inhibit OB apoptosis of estrogen is linked to
its  ability  to  increase  ERK1 and ERK2 phosphorylation and repression c-jun N-terminal
kinase (JNK) activity [25,26].
It is well recognized that c-jun N-terminal kinases (JNKs) play important roles in cellular
functions such as proliferation, differentiation, and cell death in a variety of cell types [24].
JNK activity is essential for the late-stage differentiation of osteoblasts [22].
Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in the lineage
specification of mesenchymal cells. Inactivation of ERK1 and ERK2 significantly reduced
RANKL expression, accounting for a delay in osteoclast formation. ERK1 and ERK2 not only
play essential roles in the lineage specification of osteo-chondroprogenitor cells but also
support osteoclast formation in vivo [27]. The phosphorylation of these cytoplasmic kinases
and their transport to the nucleus modulates the activity transcription factors required for
antiapoptotic actions of estrogen [16,26].
3. Estrogen loss and immune system
The immune system plays an important role in the pathophysiology of postmenopausal
osteoporosis Figure 4. Estrogen deficiency induces bone loss and increases in production of
cytokines, such as IL-1, IL-6, and TNFα. These cytokines are well known regulators of the
immune system and T cell function [1,6]. The most important cytokine in the context of
estrogen deficiency-induced bone loss has been shown to be TNFα produced by bone marrow
T lymphocytes. T lymphocytes are stimulated by a complex mechanism involving several
cytokines, such as IL-7, IFN-gamma, and TGF-beta [28].
Estrogen deficiency up-regulates TNF-alpha production by T cells through a complex pathway
relative to the thymus and bone marrow. TNF-alpha increases OC formation by up-regulating
stromal cell production of RANKL and M-CSF [28,29].
Another cytokine involving OC formation is interleukin-7 (IL-7). It has been reported that IL-7
promotes osteoclastogenesis by up-regulating T cell-derived osteoclastogenic cytokines
including RANKL [28,30,31].
INFgamma influences OC formation both via direct and indirect effects [32]. It directly blocks
OC formation and provides T cell activation inducing antigen presentation [28,33].
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Estrogen deficiency induces the imbalance between RANKL and OPG. This situation is
important in the occurance of postmenopausal bone loss [34,35].
Recent  studies  show that  postmenopausal  wonen have a  significantly  higher  concentra‐
tion of circulating sclerostin than premenopausal women [28,36]. In vivo and in vitro studies
report that TNF-alpha may stimulate the expression of sclerostin. Therefore, the increase
of sclerostin mediated by TNF-alpha may contribute to the pathogenesis of postmenopaus‐
al women [28,37].
Sclerostin is a protein encoded by the SOST gene in osteocytes. It is a modulator of osteoblast
function. Sclerostin antagonizes Wnt signaling and inhibits osteoblastic bone formation [38,
39].
Tyagi et al suggest that Th17 cells may be refer to the pathogenesis of bone loss. Th17 cells
produce IL-17. Therefore, IL-17 plays a critical role in Ovx-induced bone loss and may be
considered as a potential therapeutic target in pathogenesis of postmenopausal osteoporo‐
sis [40].
The thymus undergoes progressive structural and functional decline with age [41]. By middle
age most parenchymal tissue is replaced by fat, and fewer T cells are produced, but the thymus
progresses to generate new T cells even into old age [16,42,43]. The mechanism of thymic
Figure 4. Estrogen suppresses T cell TNF production by regulating T cell differentiation and activity in the bone mar‐
row, thymus, and peripheral lymphoid organs. In the bone marrow, estrogen downregulates the proliferation of hema‐
topoietic stem cells through an IL-7 dependent mechanism. Estrogen prevents T cell activation both directly blunting
antigen presentation and via repression of IL-7 and IFN-γ production. This effect is extended by the upregulation of
the IL-7 suppressor TGF-β. The net result of them is a decrease in the number of TNF producing T cells. The blunted
levels of TNF diminish RANKL-induced OC formation.
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rebound is not completely understood, but may be involving IL-7 [44]. IL-7 alone is not
sufficient to enhance thymopoiesis in young mice [45].
Estrogen have suppressive effect on thymic function. Estrogen deficiency induces a rebound
in thymic function. Stimulated thymic T cell output accounts for approximately 50% of the
increase in the number of T cells in the periphery. Thymectomy also reduces by approximately
50% the bone loss induced by ovariectomy (ovx). This finding shows that estrogen deficiency
induced thymic rebound may be responsible for exaggerated bone loss after surgical meno‐
pause or in the first 5-7 years after natural menopause [16].
4. Estrogen loss and oxidative stress
In fact, estrogen deficiency accelerates the effects of aging on bone by decreasing defense
against oxidative stres (OS). Estrogen protects the adult skeleton against bone loss by slowing
the rate of bone remodeling and by maintaining a focal balance between bone formation and
resorption. The acut loss of sex steroids shows an increase in the rate of bone remodeling,
resulting from an increase in both osteoclastogenesis and osteoblastogenesis [16].
Recent studies report that Reactive oxygen species (ROS) may play a role in postmenopausal
bone loss by creating a more oxidized bone microenvironment [46,47] and increase the
intracellular concentration of the antioxidant glutathione in bone prevents bone loss during
estrogen deficiency in mice [48]. Glutathione peroxidase is responsible for intracellular
degradation of hydrogen peroxide. It is the predominant antioxidant enzyme expressed by
OCs. Its overexpression abolishes OC formation [49].
Though the mechanisms of ROS action on bone during estrogen deficiency are not well-known,
it is reported that immune cells are biological targets of ROS. ROS are important stimulators
of antigen presentation by dendritic cell (DC) as well as DC-induced T cell activation [50,51].
ROS are also raised upon dendritic cell interaction with T cells [52]. ROS can decrease T cell
lifespan by stimulating T cell apoptosis [53].
It has been shown that NO donor nitroglycerin significantly prevents osteoporotic fractures
in postmenopausal women [54] and N-acetyl-cysteine (NAC) treatment prevents against ovx-
induced bone loss [48]. NAC treatment blunts ovx-induced dendritic cell activation in the bone
marrow, and prevents T cell activation and TNF-alpha production [16].
5. Conclusion
Bone tissue is continually being renewed by osteoclast and osteoblast cells during normal
physiology, but excessive resorption occurs without adequate new bone formation during
postmenopausal osteoporosis. It has been suggested that such cellular changes are a result of
postmenopausal estrogen deficiency. Recent studies report that estrogen deficiency exacer‐
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bates bone loss due to aging by diminishing the cells resistance to oxidative stres (OS).
Moreover, a relationship between the immune system and bone has been speculated.
Remarkable progression has been registered for our understanding to the mechanisms of bone
destruction during estrogen deficiency in the last 2 decades, but additional animal models and
long-term human studies are needed.
Future studies will be guide to a new therapeutic advance in the treatment of osteoporosis
with a novel mechanism of action that leads to the decrease of bone resorption and fractur risk.
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